MVC Collaborates with the US NIH to Develop Vaccine Against Corona Virus

 MVC Collaborates with the US NIH to Develop Vaccine Against Corona Virus

MVC Collaborates with the US NIH to Develop Vaccine Against Corona Virus

Shots:

  • The US NIH to provide vaccine candidates and related material to Medigen Vaccine Biologic (MVC) to initiate the preclinical development of a vaccine for Covid-19 in Taiwan
  • The results from a preclinical study will be used to assess the possibility of applying it to clinical testing on humans and developing a new generation of vaccines
  • The collaboration marks the second collaboration b/w MVC and NIH since 2015, earlier collaborated to develop a vaccine against dengue fever. Additionally, on Feb 12, 2020, MVC has applied for permission to Taiwan FDA for its RT-PCR tests kit, developed to target corona virus

Click here ­to­ read full press release/ article | Ref: The Star | Image: Sequencing

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post